Financial Incentives Boost Oncology Biosimilar Adoption, but Costs Remain Unchanged

November 20, 2024

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, biosimilar use in oncology significantly increased.

Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data

November 19, 2024

BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda

November 18, 2024

Can Global Policies to Boost Biosimilar Adoption Work in the US?

November 17, 2024

Subcutaneous Infliximab CT-P13 Superior to Placebo as Maintenance Therapy for IBD

November 16, 2024

Featured Content

The Top 5 Biosimilar Articles for the Week of November 11

November 15th 2024

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of November 11, 2024.

Breaking Down Biosimilar Barriers: Interchangeability

November 14th 2024

By Dracey Poore

Article

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.

Breaking Down Biosimilar Barriers: Payer and PBM Policies

November 13th 2024

By Skylar Jeremias

Article

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.

Overcoming Challenges to Improve Access and Reduce Costs

November 12th 2024

By Skylar Jeremias

Article

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.

Breaking Down Biosimilar Barriers: The Patent System

November 11th 2024

By Skylar Jeremias

Article

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address these challenges.

How Strategic IDNs Boost Biosimilar Adoption

November 10th 2024

By Skylar Jeremias

Video

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption.

Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD

November 9th 2024

By Deana Ferreri, PhD

Article

A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.

The Top 5 Biosimilar Articles for the Week of November 4

November 8th 2024

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of November 4, 2024.

Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo

November 7th 2024

By Skylar Jeremias

Article

For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.

Celltrion Sets Sights on 2030 With Expanded Biosimilar Portfolio, Market Reach

November 6th 2024

By Skylar Jeremias

Article

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by core biosimilars and new launches like subcutaneous infliximab.